Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based firm, ...

(Alliance News) - GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The announcement confirmed a Financial Times report published early Tuesday.

GSK has plans to takeover Nuvalent, a Boston-based clinical-stage biopharmaceutical company for 10.6 billion dollars. The biopharmaceutical firm is focused on creating precisely targeted oncology ...

LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a strategic shift under new CEO Luke ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...